Company news: IMS, BMS and AstraZeneca

Share this article:
One month after divesting itself of a promotional and medical audit business from one-time rival SDI, analytics firm IMS Health is once again expanding its reach. The Danbury, CT, company announced Tuesday it is buying the data-mining company PharmARC, which is based in Bangalore, India.

Diabetes drug dapagliflozin is facing another setback. The FDA is asking for more risk information regarding the joint AstraZeneca/Bristol-Myers pharmaceutical that is intended to treat adult diabetes 2, reports Reuters and Marketwatch. This is the third time the FDA has delayed making a decision about the SGLT2 inhibitor. The FDA indicated in July 2011 that it was alarmed by breast and bladder cancer rates among patients. Analysts note the agency is particularly skittish in light of the finding that diabetes drug Avandia was linked to heart attacks. A research note by Bernstein analyst Tim Anderson adds that the field is facing a glut, rendering the drug unwanted by diabetes experts.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.